Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies

<strong>Background</strong>—Evolocumab, a fully human monoclonal antibody to PCSK9, markedly reduces LDL-C across diverse patient populations. The objective of this study was to assess the safety and tolerability of evolocumab in a pooled safety analysis from phase 2 or 3 randomized and...

Full description

Bibliographic Details
Main Authors:	Toth, P, Descamps, O, Genest, J, Sattar, N, Preiss, D, Dent, R, Djedjos, C, Wu, Y, Geller, M, Uhart, M, Somaratne, R, Wasserman, S, for the PROFICIO Investigators
Format:	Journal article
Published:	American Heart Association 2017

Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies

Similar Items